2 weeks Ago By ABMN Staff
Ascent Group LLC increased its position in shares of AbbVie Inc. ( NYSE:ABBV – Free Report ) by 4.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.
The firm owned 25,778 shares of the company’s stock after buying an additional 1,102 shares during the period. Ascent Group LLC’s holdings in AbbVie were worth $4,421,000 at the end of the most recent quarter. Other institutional investors and hedge funds have also recently made changes to their positions in the company.
Fairway Wealth LLC bought a new stake in AbbVie during the 2nd quarter valued at $26,000. Ridgewood Investments LLC bought a new stake in AbbVie during the second quarter valued at about $27,000. Vermillion & White Wealth Management Group LLC purchased a new position in AbbVie in the fourth quarter valued at about $26,000.
IFS Advisors LLC bought a new position in AbbVie in the first quarter worth about $36,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of AbbVie during the first quarter valued at about $37,000. 70.
23% of the stock is currently owned by institutional investors. AbbVie Trading Up 1.5 % AbbVie stock opened at $194.
79 on Friday. The firm has a market cap of $343.97 billion, a PE ratio of 57.
80, a P/E/G ratio of 2.65 and a beta of 0.64.
AbbVie Inc. has a 12 month low of $135.85 and a 12 month high of $199.
95. The stock’s 50 day simple moving average is $191.54 and its two-hundred day simple moving average is $176.
25. The company has a current ratio of 0.81, a quick ratio of 0.
71 and a debt-to-equity ratio of 8.51. AbbVie Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, November 15th.
Shareholders of record on Tuesday, October 15th will be given a dividend of $1.55 per share. The ex-dividend date is Tuesday, October 15th.
This represents a $6.20 dividend on an annualized basis and a yield of 3.18%.
AbbVie’s dividend payout ratio is currently 183.98%. Analyst Upgrades and Downgrades Several research firms recently commented on ABBV.
Truist Financial reiterated a “buy” rating and set a $210.00 price objective (up previously from $195.00) on shares of AbbVie in a research note on Friday, July 26th.
Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price target on shares of AbbVie in a research report on Monday, August 5th. BMO Capital Markets raised their price objective on AbbVie from $180.
00 to $214.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Barclays boosted their target price on AbbVie from $187.
00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, July 26th. Finally, Piper Sandler increased their price target on AbbVie from $196.
00 to $209.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company.
According to data from MarketBeat, AbbVie currently has an average rating of “Buy” and an average price target of $191.64. Get Our Latest Analysis on AbbVie Insider Buying and Selling at AbbVie In other news, Chairman Richard A.
Gonzalez sold 66,500 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.
00. Following the completion of the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48.
The sale was disclosed in a filing with the SEC, which is available at this link . In related news, Chairman Richard A. Gonzalez sold 282,845 shares of AbbVie stock in a transaction dated Wednesday, July 17th.
The stock was sold at an average price of $175.00, for a total value of $49,497,875.00.
Following the sale, the chairman now directly owns 513,099 shares in the company, valued at approximately $89,792,325. The transaction was disclosed in a legal filing with the SEC, which is available at this link . Also, Chairman Richard A.
Gonzalez sold 66,500 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $186.52, for a total value of $12,403,580.
00. Following the sale, the chairman now owns 446,599 shares of the company’s stock, valued at $83,299,645.48.
The disclosure for this sale can be found here . 0.25% of the stock is owned by corporate insiders.
AbbVie Profile ( Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Recommended Stories Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.
com's FREE daily email newsletter ..
